NEWTON,
Mass., Nov. 8, 2023 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company's senior management team will participate in the following
investor conferences in November:
Jefferies 2023 London Healthcare Conference
Format:
Fireside chat
Date: Wednesday, November 15,
2023
Time: 8:00 a.m. ET / 1:00 p.m. GMT
Piper Sandler 35th Annual
Healthcare Conference
Format: Fireside chat
Date: Wednesday, November 29,
2023
Time: 4:00 p.m. ET
A live webcast of these events, along with accompanying slides,
can be accessed under "Events & Presentations" in the Investor
section of the Company's website,
http://investors.karyopharm.com/events-presentations, and will be
available for replay for 90 days following each
presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies. Since its founding, Karyopharm has been an industry
leader in oral Selective Inhibitor of Nuclear Export (SINE)
compound technology, which was developed to address a fundamental
mechanism of oncogenesis: nuclear export dysregulation.
Karyopharm's lead SINE compound and first-in-class, oral exportin 1
(XPO1) inhibitor, XPOVIO® (selinexor), is approved in
the U.S. and marketed by the Company in three oncology indications
and has received regulatory approvals in various indications in a
growing number of ex-U.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has a focused
pipeline targeting multiple high unmet need cancer indications,
including in multiple myeloma, endometrial cancer, myelodysplastic
neoplasms and myelofibrosis. For more information about our people,
science and pipeline, please visit www.karyopharm.com, and follow
us on Twitter at @Karyopharm and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-301980727.html
SOURCE Karyopharm Therapeutics Inc.